Synbiotic supplementation reduces intestinal permeability and inflammation in overweight or obese kidney transplant recipients: a randomized controlled trial
Twelve weeks of synbiotic supplementation favorably reduced intestinal permeability and systemic inflammation markers compared to placebo in 48 overweight or obese kidney transplant recipients.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Intestinal permeability (serum zonulin) | B | ▲ Favorable | Redução significativa vs placebo; IC 95% não disponível no texto fornecido | 1 |
| Systemic inflammation (hs-CRP) | B | ▲ Favorable | Redução significativa vs placebo; valores absolutos e IC 95% não disponíveis no texto fornecido | 1 |
| Vascular inflammation (ICAM-1) | C | — Insufficient | Avaliado; direção e IC 95% não verificáveis a partir do texto fornecido | 1 |
| Vascular inflammation (VCAM-1) | C | — Insufficient | Avaliado; direção e IC 95% não verificáveis a partir do texto fornecido | 1 |
| Oxidative stress (MDA) | C | — Insufficient | Avaliado; direção e IC 95% não verificáveis a partir do texto fornecido | 1 |
| Total antioxidant capacity (TAC) | C | — Insufficient | Avaliado; direção e IC 95% não verificáveis a partir do texto fornecido | 1 |
| Fibrosis (TGF-β1) | C | — Insufficient | Avaliado; direção e IC 95% não verificáveis a partir do texto fornecido | 1 |
Context
Kidney transplant recipients commonly exhibit intestinal dysbiosis, increased gut permeability, and chronic inflammation, all of which contribute to cardiovascular disease and graft failure. No prior study had tested synbiotics specifically in this population. The gut-kidney axis represents a relevant but poorly evidenced therapeutic target.
What the study showed
The synbiotic group showed statistically significant reductions in serum zonulin and hs-CRP versus placebo at 12 weeks. Complete absolute values (pre/post by group) and 95% CI for all outcomes were not fully available in the provided text, precluding precise effect size calculation. Secondary outcomes including vascular inflammation markers (ICAM-1, VCAM-1), oxidative stress (MDA, TAC), and fibrosis (TGF-β1) were assessed, but individual significance and direction could not be fully verified. No hard clinical endpoints (cardiovascular events, rejection, mortality) were reported.
How it was done
Double-blind, placebo-controlled, parallel RCT conducted December 2023 to May 2024 at a single center (Labbafi Nejad Hospital, Tehran, Iran). Forty-eight overweight or obese kidney transplant recipients were randomized to synbiotic or placebo for 12 weeks. Sample size calculation targeted a 2 mg/L difference in hs-CRP with 80% power and α=0.05.
Effect magnitude
The provided text does not supply complete absolute pre/post means per group nor 95% CI for all outcomes; effect magnitude cannot be precisely quantified from available material. The sample size (n=48) limits precision of all estimates.
Limitations
Small single-center sample (n=48) limits power for secondary outcomes and generalizability. No gut microbiota characterization prevents mechanistic attribution. Twelve-week duration precludes inference on long-term graft or cardiovascular outcomes. RoB 2 tool was not explicitly applied or reported by the authors in the available text. Geographic and cultural restriction (Iran) limits applicability to other populations.
In clinical practice
Current data do not support routine clinical recommendation of synbiotics for kidney transplant recipients. Clinicians should await replication in larger samples with hard clinical endpoints before incorporating this intervention into standard protocols. Immunosuppressive safety of synbiotics in this specific population requires further monitoring.
What is still missing
Larger, multicenter, longer-duration trials with hard outcomes (graft survival, cardiovascular events, rejection) and gut microbiota characterization are needed to establish real clinical benefit.